Back in 2011, Indian company Bharat Biotech pledged to offer its rotavirus prospect at a price that undercut even discounted vaccines from GlaxoSmithKline ($GSK) and Merck ($MRK). Now, it's ready to make good on its promise.
The country has rolled out Bharat's three-dose vaccine, Rotavac, at a rate of around 60 rupees--or just under one U.S. dollar.
"Today's launch fortifies our mission to identify public health problems and make affordable life-saving vaccines to children wherever they are born," Bharat's chairman and managing director, Krishna Ella, said in a statement.
Common Management Taxonomy: